[Congressional Bills 114th Congress] [From the U.S. Government Publishing Office] [H.R. 4982 Introduced in House (IH)] <DOC> 114th CONGRESS 2d Session H. R. 4982 To direct the Comptroller General of the United States to evaluate and report on the in-patient and outpatient treatment capacity, availability, and needs of the United States. _______________________________________________________________________ IN THE HOUSE OF REPRESENTATIVES April 18, 2016 Mr. Foster (for himself and Mr. Pallone) introduced the following bill; which was referred to the Committee on Energy and Commerce _______________________________________________________________________ A BILL To direct the Comptroller General of the United States to evaluate and report on the in-patient and outpatient treatment capacity, availability, and needs of the United States. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. SHORT TITLE. This Act may be cited as the ``Examining Opioid Treatment Infrastructure Act of 2016''. SEC. 2. STUDY ON TREATMENT INFRASTRUCTURE. Not later than 24 months after the date of enactment of this Act, the Comptroller General of the United States shall initiate an evaluation, and submit to Congress a report, of the in-patient and outpatient treatment capacity, availability, and needs of the United States, which shall include, to the extent data is available-- (1) the capacity of acute residential or inpatient detoxification programs; (2) the capacity of inpatient clinical stabilization programs, transitional residential support services, and residential rehabilitation programs; (3) the capacity of demographic specific residential or inpatient treatment programs, such as those designed for pregnant women or adolescents; (4) geographical differences of the availability of residential and outpatient treatment and recovery options for substance use disorders across the continuum of care; (5) the availability of residential and outpatient treatment programs that offer treatment options based on reliable scientific evidence of efficacy for the treatment of substance use disorders, including the use of Food and Drug Administration-approved medicines and evidence-based nonpharmacological therapies; (6) the number of patients in residential and specialty outpatient treatment services for substance use disorders; and (7) an assessment of the need for residential and outpatient treatment for substance use disorders across the continuum of care. <all>